The evolution of antiepileptic drugs for mood stabilization and their main mechanisms of action

Expert Review of Neurotherapeutics

Volumn 3, Issue 1, 2003, Pages 107-118

  Amann, Benedikt ^a   Grunze, Heinz ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AED; Bipolar disorder; Carbamazepine; Generation; Lithium; Mood stabilizer; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; CONTRACEPTIVE AGENT; ETIRACETAM; GABAPENTIN; HALOPERIDOL; HORMONE DERIVATIVE; LAMOTRIGINE; LITHIUM; LORAZEPAM; NEFAZODONE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENYTOIN; RETIGABINE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ASTHENIA; ATAXIA; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DIPLOPIA; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPONATREMIA; LEUKOCYTOSIS; LEUKOPENIA; LIVER DYSFUNCTION; MANIA; MOOD; NAUSEA; NERVOUSNESS; NYSTAGMUS; PSYCHOMOTOR DISORDER; RASH; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; TACHYCARDIA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0037229958     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.1.107     Document Type: Review

References (131)

1. Regier DA, Boyd JH, Burke JD Jr et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch. Gen. Psychiatry 45(11), 977-986 (1988).
2. Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276(4), 293-299 (1996).
3. Angst J, Gamma A. A new bipolar spectrum concept: a brief review. Bipolar Disorders 4(Suppl. 1), 11-14 (2002). Good review of the broadened bipolar spectrum.
4. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J. Clin. Psychopharmacol. 16(2 Suppl. 1), 4S-14S (1996).
5. McElroy SL, Keck PE, Pope HG et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am. J. Psychiatry 149(12), 1633-1644 (1992).
6. Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry 54(1), 37-42 (1997).
7. Cooke RG, Young LT, Levitt AJ et al. Bipolar II: Not so different when comorbidity excluded. Depression 3(3), 154-156 (1995).
8. Bowden CL. Clinical correlates of therapeutic response in bipolar disorder. J. Affect. Disord 67(1-3), 257-265 (2001).
9. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J. Affect. Disord. 43(2), 151-161 (1997).
10. Vestergaard P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 7(4), 249-259 (1992).
11. Calabrese JR, Woyshville MJ. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Ann. Clin. Psychiatry 7(2), 103-112 (1995).
12. Bourgeois ML, Hantouche EG, Akiskal HS. The Epiman and Epidep french studies of bipolarity. J. Bipolar Disorder 1(1), 13-19 (1997).
13. Bowden CL, Calabrese JR, Sachs GS et al. Lamotrigine in bipolar depression. APA Annual meeting abstracts, 244. 1998. New Research.
14. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. J. Clin. Psychiatry 60, 79-88 (1999). First controlled study demonstarting the antidepressive efficacy of LTG in bipolar I patients.
15. Mishory A, Yaroslavsky Y, Bersudsky Y et al. Phenytoin as an antimanic anticonvulsant: a controlled study. Am. J. Psychiatry 157(3), 463-465 (2000).
16. Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J. Clin. Psychiatry 48(Suppl.), 29-37 (1987).
17. Bradwejn J, Shriqui C, Koszycki D et al. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J. Clin. Psychopharmacol. 10(6), 403-408 (1990).
18. Edwards R, Stephenson U, Flewett T. Clonazepam in acute mania: a double-blind trial. Aust. NZ J. Psychiatry 25(2), 238-242 (1991).
19. Bottai T, Hue B, Hillaire-Buys D et al. Clonazepam in acute mania: time-blind evaluation of clinical response and concentrations in plasma. J. Affect. Disord. 36(1-2), 21-27 (1995).
20. Chouinard G, Annable L, Turnier L et al. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can. J. Psychiatry 38(Suppl. 4), S114-S121 (1993).
21. Sachs GS, Weilburg JB, Rosenbaum JF. Clonazepam vs. neuroleptics as adjuncts to lithium maintenance. Psychopharmacol. Bull 26(1), 137-143 (1990).
22. Aronson TA, Shukla S, Hirschowitz J. Clonazepam treatment of five lithium-refractory patients with bipolar disorder. Am. J. Psychiatry 146(1), 77-80 (1989).
23. Weiss SR, Post RM. Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Neuropsychobiology 38(3), 167-180 (1998).
24. Post RM, Ketter TA, Denicoff K et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology 128(2), 115-129 (1996).
25. Keck PE, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J. Clin. Psychopharmacol. 16(2 Suppl. 1), 15S-23S (1996).
26. Emrich HM. Studies with oxcarbazepine (Trileptal) in acute mania. Int. Clin. Psychopharmacol. 5(Suppl. 1), 83-88 (1990).
27. Müller AA, Stoll K-D. Carbamazepine and oxcarbamazepine in the treatment of manic syndromes: studies in Germany. In: Anticonvulsants in Affective Disorders. Emrich HM, Okuma T, Muller AA (Eds). Amsterdam, The Netherlands, 139-147 (1984).
28. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry 34(6), 242-250 (2001).
29. Hummel B, Walden J, Stampfer R et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord. In press.
30. Alberto G, Erickson T, Popiel R et al. Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann. Emerg. Med 18(8), 889-891 (1989).
31. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35(Suppl. 3), S10-S13 (1994).
32. Cloyd J. Pharmacokinetic pitfalls of present anti-epileptic medications. Epilepsia 32(Suppl. 5), S53-S65 (1991).
33. Hesslinger B, Normann C, Langosch JM et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J. Clin. Psychopharmacol. 19(4), 310-315 (1999).
34. Okuma T, Kishimoto A, Inoue K et al. Antimanic and prophylactic effects of carbamazepine (Tegretol®) on manic depressive psychosis. A preliminary report. Folia Psychiatr. Neurol. Jpn 27(4), 283-297 (1973).
35. Okuma T, Inanaga K, Otsuki S et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl.) 73(1), 95-96 (1981).
36. Hartong EGThM, Moleman P, Hoogduin CAL, Broekman TG, Nolen W. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J. Clin. Pychiatry (In press).
37. Greil W, Kleindienst N, Erazo N et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J. Clin. Pychopharmacol. 18, 455-460 (1998).
38. Denicoff KD, Smith-Jackson EE, Disney ER et al. Comparative prophylactic efficacy of lithium, carbamazepine and the combination in bipolar disorder. J. Clin. Psychiatry 58(11), 470-478 (1997).
39. Maj M, Pirozzi R, Magliano L et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am. J. Psychiatry 155(1), 30-35 (1998).
40. Frankenburg FR, Tohen M, Cohen BM et al. Long-term response to carbamazepine: a retrospective study. J. Clin. Psychopharmacol. 8(2), 130-132 (1988).
41. Post RM. Prophylaxis of bipolar disorders. Int. Rev. Psychiatry 2, 277-320 (1990).
42. Krüger S, Bräunig P, Young LT. Biological treatment of rapid-cycling bipolar disorder. Pharmacopsychiatry 29(5), 167-175 (1996).
43. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 27(3), 138-145 (1993).
44. Grunze H, Amann B, Walden J. How might anticonvulsant drugs work in bipolar affective disorder? In: Seizures, Affective disorders and Anticonvulsant drugs. Trimble MR, Schmitz B (Eds). Clarius Press, Guildford, UK, 117-130 (2002).
45. Lambert PA, Venaud G. Utilisation de valpromide en therapeutique psychiatrique. L'encephale 8, 367-373 (1966).
46. Emrich HM, von Zerssen D, Kissling W et al. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr. 229(1), 1-16 (1980).
47. Pope HG, McElroy SL, Keck PE et al. Valproate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psychiatry 48(1), 62-68 (1991).
48. Freeman TW, Clothier JL, Pazzaglia P et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am. J. Psychiatry 149(1), 108-111 (1992).
49. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271(12), 918-924 (1994). Important investigation demonstrating efficacy of VPA in manic patients.
50. Müller-Oerlinghausen B, Retzow A, Henn F et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania. A prospective, randomized, double-blind, placebo-controlled multicenter study. J. Clin. Psychopharmacol. 20, 195-203 (2000).
51. McElroy SL, Keck PE. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can. J. Psychiatry 38(3 Suppl. 2), S62-S66 (1993).
52. McElroy SL, Keck PE, Stanton SP et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry 57 (4), 142-146 (1996).
53. Keck PE, McElroy SL, Tugrul KC et al. Valproate oral loading in the treatment of acute mania. J. Clin. Psychiatry 54(8), 305-308 (1993).
54. Bowden CL, Janicak PG, Orsulak P et al. Relation of serum valproate concentration to response in mania. Am J. Psychiatry 153(6), 765-770 (1996).
55. Grunze H, Erfurth A, Amann B et al. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J. Clin. Psychopharmacol. 19(4), 303-309 (1999).
56. Schmidt D. Adverse effects of valproate. Epilepsia 25(Suppl. 1), S44-S49 (1984).
57. Grunze H, Walden J. Valproat bei manisch-depressiven (bipolaren) Erkrankungen. Thieme Verlag, Stuttgart, Germany (2000).
58. Sachs GS, Printz DJ, Kahn DA et al. The Expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad. Med Spec. Report 1-104 (2000).
59. Grunze H, Kasper S, Goodwin G et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part II: Treatment of Mania. World J. Biol. Psychiatry (In press).
60. Zarin D, Pincus HA, McIntyre JS. APA Practice Guideline For The Treatment Of Patients With Bipolar Disorder. www.psych.org/clin_res/pg_bipolar.cfm (2002).
61. Winsberg ME, DeGolia SG, Strong CM et al. Divalproex therapy in medicationnaive and mood-stabilizer-naive bipolar II depression. J. Affect. Disord. 67(1-3), 207-212 (2001).
62. Solomon DA, Keitner GI, Ryan CE et al. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. J. Clin. Psychopharmacol. 18(1), 38-49 (1998).
63. Burks S, Kulkarni S. The safety and efficacy of divalproex in bipolar disorder: A retrospective analysis of maintenance treatment. Proc.APA Annual Meeting, NR 332. (1996).
64. Calabrese JR, Rapport DJ, Kimmel SE et al. Rapid cycling bipolar disorder and its treatment with valproate. Can. J. Psychiatry 38(3 Suppl. 2), S57-S61 (1993).
65. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. Psychiatry 30(2), 229-233 (1974). Showed that lithium is less effective in patients with four or more affective episodes and therefore the term 'rapid cycling' was created.
66. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of out-patients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry 57, 481-489 (2000). Interesting investigation with the result that lithium as well as VPA is not superior to placebo in prophylactic treatment.
67. Grunze H, von Wegerer J, Greene RW et al. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38(3), 131-138 (1998).
68. Walden J, Hesslinger B, van Calker D et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 29(5), 193-195 (1996).
69. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am. J. Psychiatry 153(9), 1236 (1996).
70. Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J. Clin. Psychiatry 58(6), 271-273 (1997).
71. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J. Clin. Psychopharmacol. 17(3), 185-189 (1997).
72. Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am. J. Psychiatry 154(8), 1171-1172 (1997).
73. Faterni SH, Rapport DJ, Calabrese JR et al. Lamotrigine in rapid-cycling bipolar disorder. J. Clin. Psychiatry 58(12), 522-527 (1997).
74. Obrocea GV, Dunn RM, Frye MA et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol. Psychiatry 51(3), 253-260 (2002).
75. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. J. Clin. Psychiatry 61, 841-850 (2000).
76. Calabrese JR, Bowden CL, DeVeaugh-Geiss J et al. Lamotrigine demonstrates long-term mood stabilization in manic patients. APA Annual meeting abstracts 2001, NR 403. (2001).
77. Calabrese J, Bowden CL, Sachs G et al. A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients with Bipolar I Disorder. JAMA In press (2002). Important study with positive results of LTG in the prophylactic treatment of bipolar patients.
78. Erfurth A, Walden J, Grunze H. Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 38(3), 204-205 (1998).
79. Walden J, Grunze H. New Anticonvulsants in Bipolar Disorder: Lamotrigine, Gabapentin, Tiagabine. In: Seizures, Affective disorders and Anticonvulsant drugs. Trimble MR, Schmitz B (Eds). Clarius Press, Guildford, UK, 131-142 (2002).
80. Pande AC, Crockatt JG, Janney CA et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar. Disord 2(3), 249-255 (2000).
81. McElroy SL, Altshuler LL, Suppes T et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am. J. Psychiatry 158(3), 420-426 (2001).
82. Meldrum BS. Update on the mechanism of action of anti-epileptic drugs. Epilepsia 37(Suppl. 6), S4-11 (1996).
83. McElroy SL, Kmetz GF, Keck PE. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Abstr. XXIst CINP Congress, 281. (1998).
84. Normann C, Langosch J, Schaerer LO et al. Treatment of acute mania with topiramate. Am J. Psychiatry 156(12), 2014 (1999).
85. Grunze HC, Normann C, Langosch J et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J. Clin. Psychiatry 62(6), 464-468 (2001).
86. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J. Affect. Disord 50, 245-251 (1998).
87. McElroy SL, Suppes T, Keck PE et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatry 47, 1025-1033 (2000).
88. Rosenfeld WE, Schaefer PA, Pace K. Weight loss patterns with topiramate therapy. Epilepsia 38(Suppl. 3), 58 (1997).
89. Marson AG, Kadir ZA, Hutton JL et al. The new anti-epileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38(8), 859-880 (1997).
90. Jones MW. Topiramate - safety and tolerability. Can. J. Neurol. Sci. 25(3), S13-S15 (1998).
91. Stephen LJ, Maxwell JE, Brodie MJ. Transient hemiparesis with topiramate. Br. Med. J. 318(7187), 845 (1999).
92. Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. Am. J. Psychiatry 156(12), 2014-2015 (1999).
93. Grunze H, Erfurth A, Marcuse A et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J. Clin. Psychiatry 60(11), 759-762 (1999).
94. Suppes T, Chisholm, K, Dhavale D et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord (In press).
95. Carta MG, Hardoy MC, Grunze H et al. The use of tiagabine in affective disorders. Pharmacopsychiatry 35(1), 33-34 (2002).
96. Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 21 (11), 1375-1388 (2001).
97. Noyer M, Gillard M, Matagne A et al. The novel anti-epileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286(2), 137-146 (1995).
98. Klitgaard H, Matagne A, Gobert J et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353(2-3), 191-206 (1998).
99. Georg MD, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical anti-epileptic drugs. Pharmacol. Res. 42(4), 281-285 (2000).
100. Hachad H, Ragueneau-Majlessi I, Levy RH. New anti-epileptic drugs: review on drug interactions. Ther. Drug Monit. 24(1), 91-103 (2002).
101. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9(2), 80-87 (2000).
102. Goldberg JF, Burdick KE. Levetiracetam for acute mania. Am. J. Psychiatry 159(1), 148 (2002).
103. Walden J, Langosch J, Born C et al. Levetiracetam and ethosuximide in the treatment of acute mania in an open study with an on-off-on design. Bipolar Disord. 4 (Suppl. 1), 114 (2002).
104. Kanba S, Yagi G, Kamijima K et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 18(4), 707-715 (1994).
105. Tober C, Rostock A, Rundfeldt C et al. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. 303(3), 163-169 (1996).
106. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am. J. Psychiatry 155(1), 12-21 (1998).
107. Shukla S, Godwin CD, Long LE et al. Lithium-carbamazepine neurotoxicity and risk factors. Am. J. Psychiatry 141(12), 16041606 (1984).
108. Frye MA, Ketter TA, Leverich GS et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J. Clin. Psychiatry 61(1), 9-15 (2000). Interesting study showing the increasing use of combination therapy in affective disorders.
109. Grunze H, Dobmeier M. Modul Therapie akuter Episoden. In: Weissbuch Bipolare Störungen in Deutschland. Deutsche Gesellschaft für Bipolare Störungen e.V.(DGBS e.V.) (Ed.). CP-Verlag, Hamburg, Germany, 57-66 (2002).
110. Kupka RW, Nolen WA, Altshuler LL et al. The Stanley Foundation Bipolar Network: 2. Preliminary summary of demographics, course of illness and response to novel treatments. Br. J. Psychiatry 178(41), S177-S183 (2001).
111. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J. Clin. Psychiatry 63(2), 146-151 (2002).
112. Suppes T, Leverich GS, Keck PE et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J. Affect. Disord. 67(1-3), 45-59 (2001).
113. Dittmann S, Biedermann NC, Grunze H et al. The Stanley Foundation Bipolar Network: Results of the naturalistic follow-up study (NFS) after 2 1/2 years of follow-up in the German centres. Neuropsychobiology (In press).
114. Stoll AL, Severus WE. Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes. Harv. Rev. Psychiatry 4(2), 77-89 (1996).
115. Yuan PX, Huang LD, Jiang YM et al. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276(34), 31674-31683 (2001).
116. Chen G, Huang LD, Zeng WZ et al. Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability. Int. J. Neuropsychopharmacol. 4(1), 47-64 (2001).
117. Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. Br. J. Psychiatry 178(Suppl. 41), S107-S119 (2001).
118. Soares JC, Chen G, Dippold CS et al. Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Res. 95(2), 109-118 (2000).
119. Bebchuk JM, Arfken CL, Dolan MS et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 57(1), 95-97 (2000).
120. Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord. 2(3), 217-236 (2000).
121. Manji HK, Lenox RH. The nature of bipolar disorder. J. Clin. Psychiatry 61(Suppl. 13), 42-57 (2000).
122. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol. Psychiatry 48(8), 740-754 (2000).
123. Manji HK, Moore GJ, Rajkowska G et al. Neuroplasticity and cellular resilience in mood disorders. Mol. Psychiatry 5(6), 578-593 (2000).
124. Williams RS, Cheng L, Mudge AW et al. A common mechanism of action for three mood-stabilizing drugs. Nature 417(6886), 292-295 (2002).
125. Grunze H. The search for the Holy Grail - the ideal mood stabilizer: fiction or future? In: WPA Series 'Evidence Experience in Psychiatry' - Bipolar disorder. Maj M, Akiskal H, Lopez-Ibor JJ et al. (Eds). Wiley & Sons, Chichester, UK, 229-232 (2002).
126. Pande AC, PoUack MH, Crockatt J et al. Placebo-controlled study of gabapentin treatment of panic disorder. J. Clin. Psychopharmacol. 20(4), 467-471 (2000).
127. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann. Clin. Psychiatry 13(3), 141-146 (2001).
128. Crane DL. APA book of abstracts 2002, report sessions No. 120, page 48.
129. Lara ME. APA book of abstracts 2002, report sessions No. 121, page 49.
130. Ghaemi SN, Sachs GS, Chiou AM et al. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized. J. Affect. Disord. 52(1-3), 135-144 (1999).
131. Solomon DA, Ryan CE, Keitner GI et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I. J. Clin. Psychiatry 58(3), 95-99 (1997).